Back to List View Graph View

Angiogenesis

Angiogenesis is the biological process through which new blood vessels form from pre-existing vasculature.

Rebuilt from PubMed 10 Sept 2026 · no new papers today

Where the papers sit

9 papers study angiogenesis directly. Those 9 do not group into themes. Vascular growth modulation appears across cancer therapy, ischemic repair, biomaterials, and natural products. The set combines pro- and anti-angiogenic aims, including VEGF delivery, HIF-1α/CPT1 signaling, tubulin inhibition, sunitinib, lenvatinib, and PD-L1 blockade, without a common direction. They are no more alike than papers drawn from anywhere in the corpus. 1 paradigm shift follows.

PARADIGM SHIFT

Angiogenesis is presented as a therapeutic means of tissue repair rather than solely a process to suppress

The supramolecular hydrogel study of infarcted myocardium, the Danshen–Chuanxiong study in cerebral ischemia, and the protocatechualdehyde–taurine nanoparticle study of oral ulcers each treat angiogenesis as beneficial in a noncancer injury model: sustained VEGF delivery improved post-infarct repair, the herb pair alleviated cerebral ischemia while regulating angiogenesis, and the nanoparticles promoted vascularization and ulcer healing 42492872Jul 42431282Jul 41989033Apr. Against the cancer-focused use of angiogenesis inhibition elsewhere in the set, these distinct disease models and interventions indicate that the therapeutic objective is context-dependent: restoring or promoting vascular growth can itself be part of treatment when tissue ischemia or mucosal injury is the problem.

Recent Findings on angiogenesis

  • In lung adenocarcinoma, a study examined the interaction between angiogenesis and antitumor immunity in a treatment strategy combining lenvatinib, radiotherapy, and PD-L1 blockade. The cited preclinical evidence indicated that lenvatinib enhanced the efficacy of the combined treatment by modulating both angiogenesis and antitumor immunity, linking vascular-targeted therapy with immune checkpoint inhibition 42708433Sep.

  • A supramolecular recognition-based hydrogel was investigated for infarcted myocardial repair. The material incorporated VEGF and hesperadin, a CaMKII inhibitor. The publication context identifies hesperadin as having anti-apoptotic activity and VEGF as promoting angiogenesis after myocardial infarction, supporting a combined biomaterial approach directed at cell survival, vascular growth, and tissue repair 42492872Jul. The study is situated within broader efforts to use hydrogels to deliver bioactive factors for cardiac regeneration.

  • Combretastatin A4–chalcone hybrids were designed and synthesized as tubulin polymerization inhibitors. The compounds were evaluated not only for cytotoxic activity and tubulin inhibition but also for anti-angiogenic properties, reflecting the use of vascular growth inhibition as a complementary mechanism in anticancer drug discovery 42647402Aug.

  • Menstrual blood stem cell-derived exosomes were studied for their effects on breast cancer cell behavior, with particular attention to apoptosis, migration, and angiogenesis. The work therefore examined whether exosome-mediated signaling could influence several processes relevant to tumor biology, including cancer-cell movement and vascular development 42159846May. Its stated focus connects angiogenesis with cellular migration and programmed cell death rather than treating vascular growth as an isolated endpoint.

  • In liver transplant recipients with recurrent or newly developing liver cancer, a study evaluated lenvatinib together with an anti-PD-L1 agent. Lenvatinib was used as an angiogenesis-directed treatment, while PD-L1 inhibition represented the immunotherapeutic component of the combination 42262196Jun. The publication therefore reflects a therapeutic strategy that couples suppression of tumor-associated vascularization with modulation of antitumor immunity.

  • An injectable, pH-responsive gelatin methacryloyl hydrogel was developed for clear cell renal cell carcinoma. The approach combined cuproptosis-related therapy, immune reprogramming, and sunitinib treatment. Within this combination, sunitinib was described as inhibiting angiogenesis and acting synergistically with copper-driven immunomodulation to promote a tumor-suppressive M1 macrophage phenotype 42392517Jul. The study integrates vascular targeting with macrophage biology, immune response, and hydrogel-based delivery.

  • Natural polyphenoltaurine-based nanoparticles were investigated for oral-ulcer therapy. The reported therapeutic profile included reactive oxygen species scavenging, lipopolysaccharide neutralization, mitochondrial protection, modulation of macrophage polarization, promotion of anti-inflammatory activity, and enhancement of cell migration and angiogenesis 41989033Apr. In this context, angiogenesis was considered part of a broader wound-healing response involving inflammation, macrophages, tissue regeneration, and wound closure.

  • Danshen–Chuanxiong treatment was studied in cerebral ischemia using integrated multi-omics analysis. The analysis identified significant enrichment of pathways associated with carnitine metabolism and angiogenesis, and the study examined these effects in relation to activation of the CPT1/HIF-1α signaling axis 42431282Jul. This work places angiogenesis within a metabolic and hypoxia-responsive framework for ischemic brain injury.

  • Taken together, the recent publications extend the literature’s broad theme of diverse vascular therapeutics rather than defining a single unified experimental direction. They represent angiogenesis as a modifiable process in cancer, myocardial infarction, cerebral ischemia, oral-ulcer healing, and tissue-engineering applications, using small molecules, immune combinations, exosomes, nanoparticles, hydrogels, and herbal interventions. Across these settings, angiogenesis is investigated alongside endothelial-cell behavior, VEGF signaling, macrophage activity, inflammation, migration, and tissue remodeling.